TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00840658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive injection and sexual risk intervention
Description: This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Sexual Risk Intervention
Description: This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
Study: NCT03843242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with IRSplus algorithm on
Description: 1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm.
Study: NCT00655135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDP-02
Description: Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDP-02
Description: Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
Study: NCT02008240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle aspiration of hydrosalpinx
Description: Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
Study: NCT03553017

Intervention type: DEVICE
Intervention: Binocular OCT
Description: Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
Study: NCT04029532

Intervention type: DEVICE
Intervention: Respiratory exchange ratio
Description: Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.

Intervention type: DEVICE
Intervention: Respiratory exchange ratio
Description: Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.

Intervention type: DEVICE
Intervention: Heart rate variability
Description: Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.

Intervention type: DEVICE
Intervention: Heart rate variability
Description: Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.

Intervention type: DEVICE
Intervention: Body composition
Description: Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.

Intervention type: DEVICE
Intervention: Body composition
Description: Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.

Intervention type: BEHAVIORAL
Intervention: Eating behavior
Description: Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
Study: NCT02208323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: Respiratory assistance
Study: NCT00061360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG+Rapamune+cyclosporine
Description: ATG+Rapamune+cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG+cyclosporine
Description: ATG+cyclosporine
Study: NCT03930966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PDEQ, PCL-5 and demographic survey
Description: Questionnaires
Study: NCT03110328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3475
Description: anti-PD1 immunotherapy
Study: NCT04466332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeCath-CT PICC easy™ (Vygon)
Description: ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerPICC-SOLO® (C.R. Bard)
Description: ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position.
Study: NCT01062984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Venovenous Hemofiltration (CVVH)
Description: The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVH; the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Venovenous Hemodialysis (CVVHD)
Description: The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
Study: NCT03205020

Intervention type: DIAGNOSTIC_TEST
Intervention: serum amyloid a test
Description: * Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~* Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~* The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University

Intervention type: DIAGNOSTIC_TEST
Intervention: serum amyloid a test
Description: * Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~* Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~* The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University
Study: NCT01151982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention
Description: The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources.
Study: NCT02004860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic (R)
Description: Protopic® 0.1% ointment - 2 applications per week for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycoster (R)
Description: Mycoster 1% - 2 applications per week for 6 months
Study: NCT01762163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhitongluo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naoxintong Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the routine recovery training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: the routine recovery training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the routine recovery training

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04029532

Intervention type: BEHAVIORAL
Intervention: Eating behavior
Description: Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).

Intervention type: BEHAVIORAL
Intervention: Physical activity recall
Description: Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).

Intervention type: BEHAVIORAL
Intervention: Physical activity recall
Description: Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).

Intervention type: BEHAVIORAL
Intervention: Depression
Description: Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).

Intervention type: BEHAVIORAL
Intervention: Depression
Description: Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).

Intervention type: BEHAVIORAL
Intervention: Body image
Description: Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
Study: NCT02381860

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 60mL tart Montmorency cherry juice
Description: One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
Study: NCT03433092

Intervention type: OTHER
Intervention: serum carotenoids
Description: In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography

Intervention type: OTHER
Intervention: serum carotenoids
Description: In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
Study: NCT04331730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept intravitreal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept intravitreal injection
Study: NCT00891657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SprayShield™
Description: Anti-adhesion barrier
Study: NCT02743637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDX-7320
Description: SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Study: NCT04029532

Intervention type: BEHAVIORAL
Intervention: Body image
Description: Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
Study: NCT03488823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: with Flavanol
Description: Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
Study: NCT02112604

Intervention type: DEVICE
Intervention: Ventilator
Description: Mechanical ventilator used to replace or assist spontaneous breathing.

Intervention type: DEVICE
Intervention: Alice PDx
Description: Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.

Intervention type: OTHER
Intervention: Pulmonary function test
Description: The pulmonary function tests are used to study upper airway patency.

Intervention type: OTHER
Intervention: Muscle strength tests
Description: MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement

Intervention type: OTHER
Intervention: Grip strength measurement
Description: Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.

Intervention type: DRUG
Intervention: Sedatives and muscle relaxants given in the ICU
Description: Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
Study: NCT01378754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol (Lusedra®) 6.5
Description: Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol (Lusedra®) 10
Description: Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Study: NCT01378754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol (Lusedra®) 12
Description: Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Study: NCT01258829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive haemodynamic optimisation
Description: Comparing the method of non-invasive haemodynamic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECHO optimisation
Description: Standard ECHO optimisation method
Study: NCT04575350

Intervention type: GENETIC
Intervention: reinterpretation of CNV
Description: Reinterpretation of CNV of unknown significance
Study: NCT04138667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex decongestive therapy
Description: Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
Study: NCT01212328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordinator + Decision Support Software
Description: Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
Study: NCT02813330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcutaneous sterile water injection
Description: sterile water injection in two points of low back pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcutaneous sterile water injection
Description: sterile water injection in two points of low back pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline injection
Description: Saline injection in two points of low back pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline injection
Description: Saline injection in two points of low back pain
Study: NCT02812030

Intervention type: OTHER
Intervention: National Eye Institute Visual Functioning Questionnaire
Description: Routine treatment plus visual functioning questionnaires
Study: NCT01716260

Intervention type: DRUG
Intervention: Chloroquine

Intervention type: DRUG
Intervention: Primaquine
Study: NCT02890771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing with Dentifrice
Description: Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing with Dentifrice
Description: Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Turmeric Massaging
Description: :-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric Massaging
Description: :-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP with turmeric massaging
Description: on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP with turmeric massaging
Description: on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
Study: NCT01853124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidofil
Description: All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
Study: NCT01467739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu ® aScope®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a conventional reusable fiberscope
Study: NCT06695182

Intervention type: BEHAVIORAL
Intervention: physical activity